FDA Approves Mounjaro for Cardiovascular Risk Reduction in Type 2 Diabetes
The U.S. Food and Drug Administration (FDA) has granted approval for Mounjaro (tirzepatide), a medication designed to lower the risk of major cardiovascular events in individuals with type 2 diabetes who are at heightened risk. This significant decision, announced by Eli Lilly on August 28, marks an important advancement in diabetes care, particularly for patients…
